Dyslipidemia observatory: Treatment of hypercholesterolemia in Spain, context and levers for improvement in clinical practice

Cosı́n-Sales, Juan; Ruiz, Raquel Campuzano; Palencia, José Luis Díaz; Cervantes, C. Escobar; Olmo, María Rosa Fernández; Gómez‐Doblas, Juan José; Mostaza, José María; Pedro‐Botet, Juan; Gil, Núria Plana; Valdivielso, Pedro

doi:10.1016/j.artere.2022.08.003

Cited by 1 publication

(2 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Hypercholesterolemia is directly involved in the etiopathogenesis of atherosclerosis [14]. Despite this, the percentage of patients whose LDL-C levels are within therapeutic targets is very low, including patients with a higher vascular risk [16][17][18]. Although several reasons have been proposed, it seems that underestimation of the risk, as well as an inadequate perception of actual LDL-C control, play essential roles, since they lead to insufficient intensification of lipid-lowering treatment, which is key to the improvement of these figures [17,21,85].…”

Section: Discussionmentioning

confidence: 99%

See 1 more Smart Citation

Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

Mostaza,

Escobar

2024

JCM

View full text Add to dashboard Cite

Vascular diseases are the leading cause of death in Spain. Hypercholesterolemia is not only a cardiovascular risk factor, but also underlies the etiopathogenesis of atherosclerosis. Therefore, reducing LDL cholesterol (LDL-C) to the goals recommended by clinical practice guidelines, is essential to decrease the risk of vascular complications. Despite this, current LDL-C control is scarce, even in subjects with high and very high risk. This is mainly due to an insufficient intensification of lipid-lowering treatment. In this context, it is essential to prescribe the appropriate therapy, adjusted to patient’s needs based on their LDL-C and their vascular risk. Rosuvastatin, alone or in combination with ezetimibe, provides intensive LDL-C reductions (up to 50–55% and 60–75%, respectively), with a low risk of side effects and in an efficient manner, in patients both without and with established atherosclerotic vascular disease.

show abstract

Section: Discussionmentioning

confidence: 99%

“…The dyslipidemia observatory was a study carried out exclusively in Spain by 435 physicians [17]. This study recruited 4010 patients from different clinical settings (34% from cardiology, 28% from primary care, 24% from internal medicine, and 14% from endocrinology).…”

Section: Spainmentioning

confidence: 99%

Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

Mostaza,

Escobar

2024

JCM

View full text Add to dashboard Cite

show abstract

Dyslipidemia observatory: Treatment of hypercholesterolemia in Spain, context and levers for improvement in clinical practice

Cited by 1 publication

References 24 publications

Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

Rosuvastatin-Based Lipid-Lowering Therapy for the Control of LDL Cholesterol in Patients at High Vascular Risk

Contact Info

Product

Resources

About